Use of sorbents in acute renal failure and sepsis

Contributions to Nephrology

Volumn 133, Issue , 2001, Pages 180-193

  Ronco, Claudio ^a   Brendolan, Alessandra ^a   Dan, Maurizio ^a   Piccinni, Pasquale ^a   Bellomo, Rinaldo ^b   Wratten, Mary Lou ^c   Inguaggiato, Paola ^c   Tetta, Ciro ^c  

^a SAN BORTOLO HOSPITAL   (Italy)

^b AUSTIN HEALTH   (Australia)

^c Cyberonics Inc   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; ADSORPTION; HEMODIAFILTRATION; HEMOFILTRATION; HUMAN; INFECTION; METHODOLOGY; RENAL REPLACEMENT THERAPY; REVIEW;

ADSORPTION; HEMODIAFILTRATION; HEMOFILTRATION; HUMANS; INFECTION; KIDNEY FAILURE, ACUTE; RENAL REPLACEMENT THERAPY;

EID: 0035534311     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000060125     Document Type: Article

References (38)

1. Beaman M, Turney JH, Rodger RSC, McGonigle RJS, Adu D, Michael J: Changing pattern of acute renal failure. Q J Med 1987;237:15-23.
2. Schaefer JH, Jochimsen F, Keller F, Wegscheider K, Distler A: Outcome prediction of acute renal failure in medical intensive care. Intensive Care Med 1991;17:19-24.
3. Brivet FG, Kleinknecht DJ, Liorat P, Landais PJM: Acute renal failure in intensive care units Causes, outcome, and prognostic factors of hospital mortality: A prospective, multicenter study. Crit Care Med 1996;24:192-198.
4. Morrison DC, Ulevitch RY: The effects of bacterial endotoxin on host mediator system. Am J Pathol 1987;93:527-617.
5. Glauser MP, Zanetti G, Baumgartner JD, Cohen J: Septic shock: Pathogenesis. Lancet 1991;338: 732-736.
6. Zeni F, Freeman B, Nathanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997;25:1095-1100.
7. Munoz C, Carlet J, Fitting C, et al: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-1754.
8. Randow F, Syrbe V, Meisel C, et al: Mechanism of endotoxin desensitization: Involvement of interleukin-10 and transforming growth factor-β. J Exp Med 1995;181:1887-1892.
9. Gutierrez-Ramos JC, Bluethmann H: Molecules and mechanisms operating in septic shock: Lessons from knockout mice. Immunol Today 1997;18:329-334.
10. Astiz M, Saha D, Lustrader D, Lin R, Rackow E: Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J Lab Clin Med 1996;128:594-600.
11. Ionnemann G, Bechstein M, Linnenweber S, Burg M, Koch KM: Tumor necrosis factor-α during continuous high-flux hemodialysis in sepsis with acute renal failure. Kidney Int 1999;56(suppl 72): S84-S87.
12. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Mueller JM, Doecke WD, Kox WJ: Monocyte deactivation: Rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996 (suppl 4):S474-S481.
13. Brandtzaeg P, Osnes L, Ovstebo R, Joo GB, Westvik AB, Kierulf P: Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: Identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med 1996;184:51-60.
14. Liano F, Junco E, Pascual J, Madero R, Verde E, and the Madrid Acute Renal Failure Study Group: The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. Kidney Int Suppl 1998;53(66):S16-S24.
15. Bellomo R, Farmer M, Wright C, Parkin G, Boyce N: Treatment of sepsis-associated severe acute renal failure with continuous hemodiafiltration: Clinical experience and comparison with conventional dialysis. Blood Purif 1995;13:246-254.
16. Silvester W, Bellomo R, Ronco C: Continuous versus intermittent renal replacement therapy in the critically ill; in Ronco C, Bellomo R (eds): Critical Care Nephrology. Dordrecht, Kluwer Academic, 1998, pp 1225-1238.
17. Canaud B, Mion C: Extracorporeal treatment of acute renal failure: Methods, indications, quantified and personalized therapeutic approach. Adv Nephrol 1995;24:271-281.
18. Lameire N, Van Biesen W, Vanholder R: Dialysing the patient with acute renal failure in the ICU: The emperor's clothes? Nephrol Dial Transplant 1999;14:2570-2573.
19. De Vriese A, Colardyn A, Philippe JI, Vanholder RC, De Sutter JH, Lameire N: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846-853.
20. Hoffmann JN, Verdan K, Hartl WH, Jochum M, Faist E, Inthorn D: Hemofiltrate from patients with severe sepsis and depressed left ventricular contractility contains cardiotoxic compounds. Shock 1999;12:174-180.
21. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D: Hemofiltration in human sepsis: Evidence for elimination of immunomodulatory substances. Kidney Int 1995;48:1563-1570.
22. Grootendorst AF, van Bommel EF, van der Hoven B, et al: High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med 1992;18: 235-240.
23. Bellomo R, Baldwin I, Cole L, Ronco C: Preliminary experience with high-volume hemofiltration in human septic shock. Kidney Int Suppl 1998;53:66:S182-S185.
24. Ronco C, Bellomo R, Homel P, et al: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 2000;356:26-30.
25. Honore PM, Jamez J, Wauthier M, et al: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581-3587.
26. Lee PA, Matson JR, Pryor RW, Hinshaw LB: Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993;21:914-924.
27. Lonergan JM, Orlowski JP, Sato T, McHugh MJ, Zborowski M: Extracorporeal endotoxin removal in a canine model of septic shock. ASAIO J 1994;40:M654-M657.
28. Schmidt J, Mann S, Mohr VD, Lampert R, Firla U, Zingibl H: Plasmapheresis combined with continuous venovenous hemofiltration in surgical patients with sepsis. Intensive Care Med 2000; 26:532-537.
29. Tetta C, Cavaillon JM, Schulze M: Removal of cytokines and activated complement components in an experimental model of continuous plasma filtration coupled with sorbent adsorption. Nephrol Dial Transplant 1998;13:1458-1464.
30. 2-microglobulin in hemodialysis. Blood Purif 2001;19:260-263.
31. Brady JA, Potempska A, Ronco C, Yoshua E, Muller T, Levin N: Ex vivo cytokine clearance with a new adsorbent material from endotoxin-stimulated whole blood (abstract). J Am Soc Nephrol 2000; 11:586A.
32. La Greca G, Brendolan A, Ghezzi PM: The concept of sorbents in hemodialysis. Int J Artif Organs 1998;21:303-308.
33. Opal SM: Hemofiltration-adsorption systems for the treatment of experimental sepsis: Is it possible to remove the 'evil humors' responsible for septic shock? Crit Care Med 2000;28(5):1681-1682.
34. Levy H, Ash SR, Knab W, Steczko J, Carr DJ, Blake DE: Systemic inflammatory response syndrome treatment by powdered sorbent pheresis: The BioLogic-Detoxification Plasma Filtration System. ASAIO J 1998;44:M659-M665.
35. Tetta C, Gianotti L, Cavaillon JM, Wratten ML, Fini M, Braga M, Bisagni P, Giavaresi GL, Bolzani R, Giardino R: Coupled plasma filtration adsorption in a rabbit model of endotoxic shock. Crit Care Med 2000;28:1526-1533.
36. Parillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-1477.
37. Silvester W: Mediator removal with CRRT: Complement and cytokines. Am J Kidney Dis 1997; 30(suppl 5):S38-S43.
38. Brendolan A, Irone M, Digito A, et al: Coupled plasma filtration adsorption technique in sepsis-associated ARF: Hemodynamic effects. J Am Soc Nephrol 1998;9:A0655.